APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Advanced Biopharmaceutical Therapies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Advanced Biopharmaceutical Therapies Market Analysis and Forecast 2026-2032

Report ID 174052720216 April 2026199 pages

Choose your research edition.

Industry ResearchAdvanced Biopharmaceutical Therapies Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Advanced Biopharmaceutical Therapies Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Advanced Biopharmaceutical Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Advanced Biopharmaceutical Therapies Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Advanced Biopharmaceutical Therapies Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Advanced Biopharmaceutical Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Advanced Biopharmaceutical Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Advanced Biopharmaceutical Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Advanced Biopharmaceutical Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Advanced Biopharmaceutical Therapies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Advanced Biopharmaceutical Therapies include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, AGC Biologics, WuXi AppTec, Charles River Laboratories, Cytiva and Rentschler Biopharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Advanced Biopharmaceutical Therapies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Advanced Biopharmaceutical Therapies, also provides the revenue of main regions and countries. Of the upcoming market potential for Advanced Biopharmaceutical Therapies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Advanced Biopharmaceutical Therapies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Advanced Biopharmaceutical Therapies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Advanced Biopharmaceutical Therapies revenue, projected growth trends, production technology, application and end-user industry.

Advanced Biopharmaceutical Therapies Segment by Company

Lonza

Thermo Fisher Scientific

Catalent

Samsung Biologics

AGC Biologics

WuXi AppTec

Charles River Laboratories

Cytiva

Rentschler Biopharma

Oxford Biomedica

OmniaBio

Genezen

Cellipont Bioservices

VectorBuilder

Viralgen

ABL Europe

Advanced Biopharmaceutical Therapies Segment by Type

Cell Therapy Services

Gene Therapy Services

Nucleic Acid Therapy Services

Advanced Biopharmaceutical Therapies Segment by Application

Biopharmaceutical Industry

Research and Education Institutions

Others

Advanced Biopharmaceutical Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Advanced Biopharmaceutical Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Advanced Biopharmaceutical Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Advanced Biopharmaceutical Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Advanced Biopharmaceutical Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Advanced Biopharmaceutical Therapies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Advanced Biopharmaceutical Therapies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cell Therapy Services Major Player Table 3. Gene Therapy Services Major Player Table 4. Nucleic Acid Therapy Services Major Player Table 5. Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Biopharmaceutical Industry Major Player Table 7. Research and Education Institutions Major Player Table 8. Others Major Player Table 9. Advanced Biopharmaceutical Therapies Industry Trends Table 10. Advanced Biopharmaceutical Therapies Industry Drivers Table 11. Advanced Biopharmaceutical Therapies Industry Opportunities and Challenges Table 12. Advanced Biopharmaceutical Therapies Industry Restraints Table 13. Global Advanced Biopharmaceutical Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Advanced Biopharmaceutical Therapies Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Advanced Biopharmaceutical Therapies Market Share by Region (2021-2026) Table 16. Global Advanced Biopharmaceutical Therapies Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Advanced Biopharmaceutical Therapies Market Share by Region (2027-2032) Table 18. Global Advanced Biopharmaceutical Therapies Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Players (2021-2026) Table 20. Global Advanced Biopharmaceutical Therapies Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Advanced Biopharmaceutical Therapies Key Players Headquarters & Area Served Table 22. Global Advanced Biopharmaceutical Therapies Players, Product Type & Application Table 23. Global Advanced Biopharmaceutical Therapies Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Advanced Biopharmaceutical Therapies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Advanced Biopharmaceutical Therapies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Type (2021-2026) Table 30. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Type (2027-2032) Table 31. Global Advanced Biopharmaceutical Therapies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Application (2021-2026) Table 35. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Application (2027-2032) Table 36. Lonza Company Information Table 37. Lonza Business Overview Table 38. Lonza Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Lonza Advanced Biopharmaceutical Therapies Product Portfolio Table 40. Lonza Recent Development Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Catalent Company Information Table 47. Catalent Business Overview Table 48. Catalent Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Catalent Advanced Biopharmaceutical Therapies Product Portfolio Table 50. Catalent Recent Development Table 51. Samsung Biologics Company Information Table 52. Samsung Biologics Business Overview Table 53. Samsung Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio Table 55. Samsung Biologics Recent Development Table 56. AGC Biologics Company Information Table 57. AGC Biologics Business Overview Table 58. AGC Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio Table 60. AGC Biologics Recent Development Table 61. WuXi AppTec Company Information Table 62. WuXi AppTec Business Overview Table 63. WuXi AppTec Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio Table 65. WuXi AppTec Recent Development Table 66. Charles River Laboratories Company Information Table 67. Charles River Laboratories Business Overview Table 68. Charles River Laboratories Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio Table 70. Charles River Laboratories Recent Development Table 71. Cytiva Company Information Table 72. Cytiva Business Overview Table 73. Cytiva Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Cytiva Advanced Biopharmaceutical Therapies Product Portfolio Table 75. Cytiva Recent Development Table 76. Rentschler Biopharma Company Information Table 77. Rentschler Biopharma Business Overview Table 78. Rentschler Biopharma Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio Table 80. Rentschler Biopharma Recent Development Table 81. Oxford Biomedica Company Information Table 82. Oxford Biomedica Business Overview Table 83. Oxford Biomedica Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio Table 85. Oxford Biomedica Recent Development Table 86. OmniaBio Company Information Table 87. OmniaBio Business Overview Table 88. OmniaBio Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio Table 90. OmniaBio Recent Development Table 91. Genezen Company Information Table 92. Genezen Business Overview Table 93. Genezen Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Genezen Advanced Biopharmaceutical Therapies Product Portfolio Table 95. Genezen Recent Development Table 96. Cellipont Bioservices Company Information Table 97. Cellipont Bioservices Business Overview Table 98. Cellipont Bioservices Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio Table 100. Cellipont Bioservices Recent Development Table 101. VectorBuilder Company Information Table 102. VectorBuilder Business Overview Table 103. VectorBuilder Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio Table 105. VectorBuilder Recent Development Table 106. Viralgen Company Information Table 107. Viralgen Business Overview Table 108. Viralgen Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Viralgen Advanced Biopharmaceutical Therapies Product Portfolio Table 110. Viralgen Recent Development Table 111. ABL Europe Company Information Table 112. ABL Europe Business Overview Table 113. ABL Europe Advanced Biopharmaceutical Therapies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio Table 115. ABL Europe Recent Development Table 116. North America Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Advanced Biopharmaceutical Therapies Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Advanced Biopharmaceutical Therapies Revenue by Country (US$ Million) & (2027-2032) Table 130. China Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 131. China Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 132. China Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 133. China Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Advanced Biopharmaceutical Therapies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Advanced Biopharmaceutical Therapies Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Advanced Biopharmaceutical Therapies Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Advanced Biopharmaceutical Therapies Image Figure 2. Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Advanced Biopharmaceutical Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cell Therapy Services Image Figure 5. Gene Therapy Services Image Figure 6. Nucleic Acid Therapy Services Image Figure 7. Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Advanced Biopharmaceutical Therapies Market Size Share 2021 VS 2025 VS 2032 Figure 9. Biopharmaceutical Industry Image Figure 10. Research and Education Institutions Image Figure 11. Others Image Figure 12. Global Advanced Biopharmaceutical Therapies Market Size (US$ Million) & (2021-2032) Figure 13. Global Advanced Biopharmaceutical Therapies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Advanced Biopharmaceutical Therapies Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Advanced Biopharmaceutical Therapies Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Advanced Biopharmaceutical Therapies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Advanced Biopharmaceutical Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Type (2021-2032) Figure 20. Global Advanced Biopharmaceutical Therapies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Advanced Biopharmaceutical Therapies Revenue Market Share by Application (2021-2032) Figure 23. North America Advanced Biopharmaceutical Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032) Figure 25. North America Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032) Figure 26. North America Advanced Biopharmaceutical Therapies Revenue Share by Country (2021-2032) Figure 27. United States Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Advanced Biopharmaceutical Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032) Figure 32. Europe Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032) Figure 33. Europe Advanced Biopharmaceutical Therapies Revenue Share by Country (2021-2032) Figure 34. Germany Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Advanced Biopharmaceutical Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032) Figure 44. China Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032) Figure 45. Asia Advanced Biopharmaceutical Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032) Figure 47. Asia Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032) Figure 48. Asia Advanced Biopharmaceutical Therapies Revenue Share by Region (2021-2032) Figure 49. Japan Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Advanced Biopharmaceutical Therapies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032) Figure 57. SAMEA Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032) Figure 58. SAMEA Advanced Biopharmaceutical Therapies Revenue Share by Country (2021-2032) Figure 59. Brazil Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Advanced Biopharmaceutical Therapies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Therapy Services
  • Gene Therapy Services
  • Nucleic Acid Therapy Services
Applications
  • Biopharmaceutical Industry
  • Research and Education Institutions
  • Others
Companies covered
  • Lonza
  • Thermo Fisher Scientific
  • Catalent
  • Samsung Biologics
  • AGC Biologics
  • WuXi AppTec
  • Charles River Laboratories
  • Cytiva
  • Rentschler Biopharma
  • Oxford Biomedica
  • OmniaBio
  • Genezen
  • Cellipont Bioservices
  • VectorBuilder
  • Viralgen
  • ABL Europe

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Advanced Biopharmaceutical Therapies Market by Type
  3. 1.2.1 Global Advanced Biopharmaceutical Therapies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cell Therapy Services
  5. 1.2.3 Gene Therapy Services
  6. 1.2.4 Nucleic Acid Therapy Services
  7. 1.3 Advanced Biopharmaceutical Therapies Market by Application
  8. 1.3.1 Global Advanced Biopharmaceutical Therapies Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Biopharmaceutical Industry
  10. 1.3.3 Research and Education Institutions
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Advanced Biopharmaceutical Therapies Market Dynamics
  1. 2.1 Advanced Biopharmaceutical Therapies Industry Trends
  2. 2.2 Advanced Biopharmaceutical Therapies Industry Drivers
  3. 2.3 Advanced Biopharmaceutical Therapies Industry Opportunities and Challenges
  4. 2.4 Advanced Biopharmaceutical Therapies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Advanced Biopharmaceutical Therapies Market Perspective (2021-2032)
  2. 3.2 Global Advanced Biopharmaceutical Therapies Growth Trends by Region
  3. 3.2.1 Global Advanced Biopharmaceutical Therapies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Advanced Biopharmaceutical Therapies Market Size by Region (2021-2026)
  5. 3.2.3 Global Advanced Biopharmaceutical Therapies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Advanced Biopharmaceutical Therapies Revenue by Players
  2. 4.1.1 Global Advanced Biopharmaceutical Therapies Revenue by Players (2021-2026)
  3. 4.1.2 Global Advanced Biopharmaceutical Therapies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Advanced Biopharmaceutical Therapies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Advanced Biopharmaceutical Therapies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Advanced Biopharmaceutical Therapies Key Players Headquarters & Area Served
  7. 4.4 Global Advanced Biopharmaceutical Therapies Players, Product Type & Application
  8. 4.5 Global Advanced Biopharmaceutical Therapies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Advanced Biopharmaceutical Therapies Market CR5 and HHI
  11. 4.6.3 2025 Advanced Biopharmaceutical Therapies Tier 1, Tier 2, and Tier 3
5 Advanced Biopharmaceutical Therapies Market Size by Type
  1. 5.1 Global Advanced Biopharmaceutical Therapies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 5.3 Global Advanced Biopharmaceutical Therapies Revenue Market Share by Type (2021-2032)
6 Advanced Biopharmaceutical Therapies Market Size by Application
  1. 6.1 Global Advanced Biopharmaceutical Therapies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  3. 6.3 Global Advanced Biopharmaceutical Therapies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Advanced Biopharmaceutical Therapies Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Thermo Fisher Scientific
  8. 7.2.1 Thermo Fisher Scientific Company Information
  9. 7.2.2 Thermo Fisher Scientific Business Overview
  10. 7.2.3 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio
  12. 7.2.5 Thermo Fisher Scientific Recent Developments
  13. 7.3 Catalent
  14. 7.3.1 Catalent Company Information
  15. 7.3.2 Catalent Business Overview
  16. 7.3.3 Catalent Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Catalent Advanced Biopharmaceutical Therapies Product Portfolio
  18. 7.3.5 Catalent Recent Developments
  19. 7.4 Samsung Biologics
  20. 7.4.1 Samsung Biologics Company Information
  21. 7.4.2 Samsung Biologics Business Overview
  22. 7.4.3 Samsung Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio
  24. 7.4.5 Samsung Biologics Recent Developments
  25. 7.5 AGC Biologics
  26. 7.5.1 AGC Biologics Company Information
  27. 7.5.2 AGC Biologics Business Overview
  28. 7.5.3 AGC Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio
  30. 7.5.5 AGC Biologics Recent Developments
  31. 7.6 WuXi AppTec
  32. 7.6.1 WuXi AppTec Company Information
  33. 7.6.2 WuXi AppTec Business Overview
  34. 7.6.3 WuXi AppTec Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio
  36. 7.6.5 WuXi AppTec Recent Developments
  37. 7.7 Charles River Laboratories
  38. 7.7.1 Charles River Laboratories Company Information
  39. 7.7.2 Charles River Laboratories Business Overview
  40. 7.7.3 Charles River Laboratories Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio
  42. 7.7.5 Charles River Laboratories Recent Developments
  43. 7.8 Cytiva
  44. 7.8.1 Cytiva Company Information
  45. 7.8.2 Cytiva Business Overview
  46. 7.8.3 Cytiva Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Cytiva Advanced Biopharmaceutical Therapies Product Portfolio
  48. 7.8.5 Cytiva Recent Developments
  49. 7.9 Rentschler Biopharma
  50. 7.9.1 Rentschler Biopharma Company Information
  51. 7.9.2 Rentschler Biopharma Business Overview
  52. 7.9.3 Rentschler Biopharma Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio
  54. 7.9.5 Rentschler Biopharma Recent Developments
  55. 7.10 Oxford Biomedica
  56. 7.10.1 Oxford Biomedica Company Information
  57. 7.10.2 Oxford Biomedica Business Overview
  58. 7.10.3 Oxford Biomedica Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio
  60. 7.10.5 Oxford Biomedica Recent Developments
  61. 7.11 OmniaBio
  62. 7.11.1 OmniaBio Company Information
  63. 7.11.2 OmniaBio Business Overview
  64. 7.11.3 OmniaBio Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  65. 7.11.4 OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio
  66. 7.11.5 OmniaBio Recent Developments
  67. 7.12 Genezen
  68. 7.12.1 Genezen Company Information
  69. 7.12.2 Genezen Business Overview
  70. 7.12.3 Genezen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Genezen Advanced Biopharmaceutical Therapies Product Portfolio
  72. 7.12.5 Genezen Recent Developments
  73. 7.13 Cellipont Bioservices
  74. 7.13.1 Cellipont Bioservices Company Information
  75. 7.13.2 Cellipont Bioservices Business Overview
  76. 7.13.3 Cellipont Bioservices Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio
  78. 7.13.5 Cellipont Bioservices Recent Developments
  79. 7.14 VectorBuilder
  80. 7.14.1 VectorBuilder Company Information
  81. 7.14.2 VectorBuilder Business Overview
  82. 7.14.3 VectorBuilder Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  83. 7.14.4 VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio
  84. 7.14.5 VectorBuilder Recent Developments
  85. 7.15 Viralgen
  86. 7.15.1 Viralgen Company Information
  87. 7.15.2 Viralgen Business Overview
  88. 7.15.3 Viralgen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Viralgen Advanced Biopharmaceutical Therapies Product Portfolio
  90. 7.15.5 Viralgen Recent Developments
  91. 7.16 ABL Europe
  92. 7.16.1 ABL Europe Company Information
  93. 7.16.2 ABL Europe Business Overview
  94. 7.16.3 ABL Europe Advanced Biopharmaceutical Therapies Revenue and Gross Margin (2021-2026)
  95. 7.16.4 ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio
  96. 7.16.5 ABL Europe Recent Developments
8 North America
  1. 8.1 North America Advanced Biopharmaceutical Therapies Revenue (2021-2032)
  2. 8.2 North America Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 8.2.1 North America Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026)
  4. 8.2.2 North America Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032)
  5. 8.3 North America Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032)
  6. 8.4 North America Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  7. 8.4.1 North America Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026)
  8. 8.4.2 North America Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032)
  9. 8.5 North America Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032)
  10. 8.6 North America Advanced Biopharmaceutical Therapies Revenue by Country
  11. 8.6.1 North America Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026)
  13. 8.6.3 North America Advanced Biopharmaceutical Therapies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Advanced Biopharmaceutical Therapies Revenue (2021-2032)
  2. 9.2 Europe Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 9.2.1 Europe Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026)
  4. 9.2.2 Europe Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032)
  5. 9.3 Europe Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032)
  6. 9.4 Europe Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  7. 9.4.1 Europe Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026)
  8. 9.4.2 Europe Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032)
  9. 9.5 Europe Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032)
  10. 9.6 Europe Advanced Biopharmaceutical Therapies Revenue by Country
  11. 9.6.1 Europe Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026)
  13. 9.6.3 Europe Advanced Biopharmaceutical Therapies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Advanced Biopharmaceutical Therapies Revenue (2021-2032)
  2. 10.2 China Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 10.2.1 China Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026)
  4. 10.2.2 China Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032)
  5. 10.3 China Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032)
  6. 10.4 China Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  7. 10.4.1 China Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026)
  8. 10.4.2 China Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032)
  9. 10.5 China Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Advanced Biopharmaceutical Therapies Revenue (2021-2032)
  2. 11.2 Asia Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 11.2.1 Asia Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026)
  4. 11.2.2 Asia Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032)
  5. 11.3 Asia Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032)
  6. 11.4 Asia Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  7. 11.4.1 Asia Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026)
  8. 11.4.2 Asia Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032)
  9. 11.5 Asia Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032)
  10. 11.6 Asia Advanced Biopharmaceutical Therapies Revenue by Country
  11. 11.6.1 Asia Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026)
  13. 11.6.3 Asia Advanced Biopharmaceutical Therapies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Advanced Biopharmaceutical Therapies Revenue (2021-2032)
  2. 12.2 SAMEA Advanced Biopharmaceutical Therapies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Advanced Biopharmaceutical Therapies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Advanced Biopharmaceutical Therapies Revenue by Type (2027-2032)
  5. 12.3 SAMEA Advanced Biopharmaceutical Therapies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Advanced Biopharmaceutical Therapies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Advanced Biopharmaceutical Therapies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Advanced Biopharmaceutical Therapies Revenue by Application (2027-2032)
  9. 12.5 SAMEA Advanced Biopharmaceutical Therapies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Advanced Biopharmaceutical Therapies Revenue by Country
  11. 12.6.1 SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Advanced Biopharmaceutical Therapies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst